glp-1 agonist therapy Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Researchers find GLP-1 medications safe

4,5 Current Treatment Options for T2D Oftentimes, the first form of treatment for patients with T2D is lifestyle intervention

Higher doses of dulaglutide9 and semaglutide10 have demonstrated improved weight reduction and glycemic control in T2DM patients

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the management of type 2 diabetes, have gained prominence in managing obesity, offering clinically meaningful weight loss of 1520% in many clinical trials

Manufacturer: Novo Nordisk List price (USA): According to Novo Nordisk, the list price of Victoza is as follows: 2-Pen Package (0.6 & 1.2 mg doses): $543.51

Considerable expenditure will be necessary for research and development, formulation development, clinical trials, and gaining regulatory approval

Indiana University researcher Richard DiMarchi played a crucial role in the development of GLP-1 drugs for obesity treatment